385 related articles for article (PubMed ID: 27462073)
1. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
[TBL] [Abstract][Full Text] [Related]
2. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.
Lin Y; Marin-Argany M; Dick CJ; Redhage KR; Blancas-Mejia LM; Bulur P; Butler GW; Deeds MC; Madden BJ; Williams A; Wall JS; Dietz A; Ramirez-Alvarado M
Cytotherapy; 2017 Dec; 19(12):1426-1437. PubMed ID: 29037943
[TBL] [Abstract][Full Text] [Related]
4. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
6. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation.
Blancas-Mejía LM; Misra P; Ramirez-Alvarado M
Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646
[TBL] [Abstract][Full Text] [Related]
7. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
[TBL] [Abstract][Full Text] [Related]
9. Antibodies gone bad - the molecular mechanism of light chain amyloidosis.
Absmeier RM; Rottenaicher GJ; Svilenov HL; Kazman P; Buchner J
FEBS J; 2023 Mar; 290(6):1398-1419. PubMed ID: 35122394
[TBL] [Abstract][Full Text] [Related]
10. Seeded fibrils of the germline variant of human λ-III immunoglobulin light chain FOR005 have a similar core as patient fibrils with reduced stability.
Pradhan T; Annamalai K; Sarkar R; Huhn S; Hegenbart U; Schönland S; Fändrich M; Reif B
J Biol Chem; 2020 Dec; 295(52):18474-18484. PubMed ID: 33093170
[TBL] [Abstract][Full Text] [Related]
11. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
Martin DJ; Ramirez-Alvarado M
Amyloid; 2010 Sep; 17(3-4):129-36. PubMed ID: 21077798
[TBL] [Abstract][Full Text] [Related]
12. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
[TBL] [Abstract][Full Text] [Related]
13. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
[TBL] [Abstract][Full Text] [Related]
14. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
15. Thermal stability threshold for amyloid formation in light chain amyloidosis.
Poshusta TL; Katoh N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M
Int J Mol Sci; 2013 Nov; 14(11):22604-17. PubMed ID: 24248061
[TBL] [Abstract][Full Text] [Related]
16. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
[TBL] [Abstract][Full Text] [Related]
17. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
[TBL] [Abstract][Full Text] [Related]
18. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils.
Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M
Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Insights into the Early Events in the Aggregation of Immunoglobulin Light Chains.
Misra P; Blancas-Mejia LM; Ramirez-Alvarado M
Biochemistry; 2019 Jul; 58(29):3155-3168. PubMed ID: 31287666
[TBL] [Abstract][Full Text] [Related]
20. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
